Invitation Homes (NYSE:INVH) Stock

INVITATION HOMES INC

Invitation Homes

Invitation Homes owns a portfolio of over 85,000 single-family rental homes. The company focuses on owning homes in the starter and move-up segments of the housing market with an average sale price around $350,000 and generally less than 1,800 square feet. The portfolio is spread across 16 target markets that feature high employment and household formation growth with almost 70% of the portfolio in the Western U.S. and Florida; 15 of the 16 markets featuring average rents lower than homeownership costs.

Invitation Homes Inc

<ul>
<li>KINECT-PRO is the first and only study to specifically evaluate and demonstrate patient-reported improvement with vesicular monoamine transporter 2 inhibitor treatment on tardive dyskinesia using multiple clinically validated scales</li>
<li>Patients taking INGREZZA reported robust and clinically meaningful improvements in physical, social and emotional functioning</li>
<li>Improvements were seen as early as Week 4 after initial treatment with the lowest INGREZZA dose and sustained through Week 24</li>
<li>Even patients with milder uncontrolled movement severity were negatively impacted by their tardive dyskinesia at baseline and demonstrated meaningful improvements in tardive dyskinesia impact with INGREZZA treatment</li>
</ul>
SAN DIEGO, June 2, 2025 /PRNewswire/ --&nbsp;<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4439241-1&amp;h=2727807877&amp;u=https%3A%2F%2Fwww.neurocrine.com%2F&amp;a=Neurocrine+Biosciences%2C+Inc.">Neurocrine Biosciences, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBIX#NASDAQ">NBIX</a>) today announced new data from the Phase 4 KINECT-PROTM open-label study demonstrating robust and sustained improvements in physical, social and emotional functioning in patients with tardive dyskinesia taking once-daily INGREZZA&#xAE; (valbenazine) capsules. KINECT-PRO is the first and only study to specifically evaluate and demonstrate patient-reported improvement with vesicular monoamine transporter 2 inhibitor treatment, specifically INGREZZA, on tardive dyskinesia using multiple clinically validated scales, including the <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4439241-1&amp;h=1411550016&amp;u=https%3A%2F%2Fjpro.springeropen.com%2Farticles%2F10.1186%2Fs41687-023-00679-4&amp;a=Tardive+Dyskinesia+Impact+Scale">Tardive Dyskinesia Impact Scale</a>. The Tardive Dyskinesia Impact Scale is the only patient-reported outcome instrument designed for and validated in tardive dyskinesia patients that measures the physical, social and emotional impact of the involuntary movements of the condition. These results were presented at 2025 Psych Congress Elevate in Las Vegas.

News

NBIX

Neurocrine Biosciences Announces New Data From Phase 4 KINECT-PROTM Open-Label Study Showing Robust, Sustained Improvements In Physical, Social And Emotional Functioning In Patients With Tardive Dyskinesia Taking Once-Daily INGREZZA Capsules

Company's PALISADE-4 Phase 3 trial now expected to read out in the first half of 2026

Biotech

General

VTGN

Vistagen Therapeutics Provides Update For U.S. Registration-Directed PALISADE-3 Phase 3 Trial Evaluating Fasedienol For Acute Treatment Of Social Anxiety Disorder

Keefe, Bruyette &amp; Woods analyst Kyle Voigt maintains Hamilton Lane (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HLNE#NASDAQ">HLNE</a>) with a Market Perform and lowers the price target from $162 to $155.

Price Target

Analyst Ratings

HLNE

Keefe, Bruyette & Woods Maintains Market Perform on Hamilton Lane, Lowers Price Target to $155

WIIM

WETO

Webush International shares are trading higher after the company announced it signed a $300 million XRP treasury management agreement with Samara Alpha.

Ladenburg Thalmann analyst Paul Fremont downgrades NorthWestern Energy Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NWE#NASDAQ">NWE</a>) from Buy to Neutral and lowers the price target from $57.5 to $56.

Downgrades

Ladenburg Thalmann Downgrades NorthWestern Energy Group to Neutral, Lowers Price Target to $56

Classover Holdings, Inc. (NASDAQ:<a href="https://www.benzinga.com/stock/KIDZ#NASDAQ">KIDZ</a>, KIDZW)) ("Classover" or the "Company"), a leading provider of live, interactive online learning, today announced it has entered into a securities purchase agreement with Solana Growth Ventures LLC for the issuance of up to $500 million in senior secured convertible notes, advancing its strategic initiative to build a Solana (SOL)-based treasury reserve
Key Highlights:
- The securities purchase agreement provides for the issuance of up to $500 million in senior secured convertible notes. An initial closing and funding of $11 million is expected to occur promptly after customary closing conditions have been satisfied.
- The notes may be converted by the holder into the Company's Class B common stock at an initial conversion price equal to 200% of the closing price of the Company's Class B common stock on the trading day immediately prior to the closing date, subject to adjustment as provided for in the notes.
- Under the agreement, Classover is required to allocate up to 80% of the net proceeds toward purchases of SOL (Solana), subject to certain terms and limitations.
- This new agreement complements Classover's previously announced $400 million equity purchase agreement, increasing the Company's total potential financing capacity to $900 million, dedicated to supporting its SOL acquisition strategy.
- Prior to this agreement, Classover had already initiated its SOL reserve strategy, having purchased 6,472 SOL for approximately $1.05 million - marking the first step in its long-term strategy to acquire, hold, and stake Solana ("SOL") tokens.
The Company is also exploring opportunities for acquiring discounted blocks of locked tokens, as part of its broader accumulation and treasury strategy.

KIDZ

KIDZW

Classover Holdings Enters Into Securities Purchase Agreement With Solana Growth Ventures For Issuance Of Up To $500M In Senior Secured Convertible Notes, Advancing Strategic Initiative To Build Solana-Based Treasury Reserve

Management

TELA

TELA Bio Appoints Jeffrey Blizard As President Effective Immediately

Dollar General Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DG#NYSE">DG</a>) will release its first-quarter financial results before the opening <a href="https://www.benzinga.com/quote/DG/earnings">bell on Tuesday, June 3.</a>
Analysts expect the company to report quarterly earnings at $1.49 per share, down from $1.65 per share in the year-ago period. Dollar General projects quarterly revenue of $10.29 billion, compared to $9.91 billion a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
On May 29, UBS analyst Michael Lasser maintained Dollar General with a Buy rating and raised the price target from $95 to $120.
With the recent buzz around Dollar General, some investors may be eyeing potential gains from the company's dividends too. As of now, Dollar General offers an annual dividend yield of 2.43%, which is a quarterly dividend amount of 59 cents per share ($2.36 a year).
To figure out how to earn $500 monthly from Dollar General, we start with the yearly target of $6,000 ($500 x 12 months).
Next, we take this amount and divide it by Dollar General's $2.36 dividend: $6,000 / 2.36 = 2,542 shares.
So, an investor would need to own approximately $247,210 worth of Dollar General, or 2,542 shares to generate a monthly dividend income of $500.
Assuming a more conservative goal of $100 monthly ($1,200 annually), we do the same calculation: $1,200 / $1.158 = 508 shares, or $49,403 to generate a monthly dividend income of $100.
Note that dividend yield can change on a rolling basis, as the dividend payment and the stock price both fluctuate over time.
The dividend yield is calculated by dividing the annual dividend payment by the current stock price. As the stock price changes, the dividend yield will also change.
For example, if a stock pays an annual dividend of $2 and its current price is $50, its dividend yield would be 4%. However, if the stock price increases to $60, the dividend yield would decrease to 3.33% ($2/$60).
Conversely, if the stock price decreases to $40, the dividend yield would increase to 5% ($2/$40).
Further, the dividend payment itself can also change over time, which can also impact the dividend yield. If a company increases its dividend payment, the dividend yield will increase even if the stock price remains the same. Similarly, if a company decreases its dividend payment, the dividend yield will decrease.
DG Price Action: Shares of Dollar General gained by 0.2% to close at $97.25 on Friday.
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/04/38289870/top-5-tech-and-telecom-stocks-that-may-rocket-higher-this-month">Top 5 Tech And Telecom Stocks That May Rocket Higher This Month</a></li>
</ul>
Photo: Shutterstock

Long Ideas

Markets

How To Earn $500 A Month From Dollar General Stock Ahead Of Q1 Earnings

ARVN

Arvinas shares are trading lower after Leerink Partners downgraded the stock from Outperform to Market Perform and cut its price target from $10 to $9.

TruGolf Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRUG#NASDAQ">TRUG</a>), a leading golf technology company, today announced that the Nasdaq Hearings Panel has granted the company an extension of time to comply with Nasdaq listing rules subject to panel conditions. The Company's listing will be transferred to the Capital Market, effective at the open of business on June 3, 2025.&nbsp;

TRUG

TruGolf Secures Nasdaq Compliance Extension, Subject To Panel Conditions

Galloway Capital Partners And Affiliate, Diveroli Investment Group, Announces 4.31% Stake in Babcock & Wilcox Enterprises

KURA

Kura Oncology shares are trading higher after the company announced the  FDA has granted it acceptance and priority review for Ziftomenib.

Litchfield Hills analyst Theodore O'Neill initiates coverage on Inspira Technologies Oxy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IINN#NASDAQ">IINN</a>) with a Buy rating and announces Price Target of $2.

Initiation

Inspira Technologies Oxy BHN Ltd Ordinary Shares

IINN

Litchfield Hills Initiates Coverage On Inspira Technologies Oxy with Buy Rating, Announces Price Target of $2

Both ERAS-4001 and potential best-in-class pan-RAS molecular glue ERAS-0015 received IND clearance in May ahead of company guidance
Initial Phase 1 monotherapy data for both RAS-targeting programs expected in 2026
SAN DIEGO, June 02, 2025 (GLOBE NEWSWIRE) -- Erasca, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ERAS#NASDAQ">ERAS</a>), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced clearance of an investigational new drug (IND) application by the United States Food and Drug Administration (FDA) for ERAS-4001, a potential first-in-class and best-in-class pan-KRAS inhibitor, for the treatment of patients with KRAS-mutant (KRASm) solid tumors.

ERAS

Erasca Secures FDA Clearance For First-In-Class Pan-KRAS Inhibitor ERAS-4001

LQDA

Liquidia shares are trading higher after the company announced it began shipping its newly FDA-approved Yutrepia. Additionally, Needham raised its price target on the stock from $25 to $32.

Lyra Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LYRA#NASDAQ">LYRA</a>) released results on Monday from the ENLIGHTEN 2 Phase 3 trial of LYR-210 in adult patients with <a href="https://www.benzinga.com/general/health-care" target="_blank" rel="noreferrer noopener">Chronic Rhinosinusitis (CRS)</a>.
The ENLIGHTEN 2 trial met its primary endpoint, with LYR-210 demonstrating statistically significant improvement compared to sham control in a composite of the three cardinal symptoms (3CS) of CRS (nasal obstruction, nasal discharge, facial pain/pressure) at week 24 (p=0.0078) in patients without nasal polyps.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/03/44083934/amgen-astrazeneca-partnered-asthma-drug-shows-rapid-and-sustained-effect-in-chronic-rhinosinusitis" rel="noreferrer noopener">Amgen-AstraZeneca Partnered Asthma Drug Shows Rapid And Sustained Effect In Chronic Rhinosinusitis</a>
The ENLIGHTEN 2 trial also met the key secondary endpoints of 3CS at 24 weeks in the full population (i.e., patients with and without nasal polyps) and in the clinically validated SNOT-22 score at 24 weeks, with symptom improvement <a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/g45717754/lyra-therapeutics-reports-positive-results-from-the-enlighten-2-phase-3-trial-of-lyr-210-achieving" rel="noreferrer noopener">observed as early as week 4</a>.
<ul class="wp-block-list">
<li>Improvements in SNOT-22 were sustained throughout the trial and were clinically meaningful. More than twice the minimal clinically important difference was observed at week 24 compared to baseline in the LYR-210 group (-22.4 points).</li>
</ul>
Consistent with previous studies, LYR-210 was well-tolerated, with a safety profile similar to sham control.
Data evaluating computed tomography (CT) scans demonstrated numerical improvement in ethmoid sinus opacification in patients who received LYR-210, compared to sham control at week 20 (-2.15; p=0.1809). These data provide objective radiological evidence of improvement with LYR-210 treatment.
<ul class="wp-block-list">
<li>LYR-210 patients showed no difference from sham patients in using corticosteroid rescue medication; however, the LYR-210 patients had fewer endoscopic sinus surgeries than sham control.</li>
</ul>
LYR-210 was well tolerated, with no product-related serious adverse events in the ENLIGHTEN 2 trial.
The ENLIGHTEN program consists of two Phase 3 trials, ENLIGHTEN 1 and ENLIGHTEN 2, to evaluate the efficacy and safety of LYR-210 for CRS.
<ul class="wp-block-list">
<li>While the ENLIGHTEN 2 trial met its primary endpoint and key secondary endpoints, the ENLIGHTEN 1 trial did not meet the primary or secondary endpoints, as&nbsp;<a href="https://www.benzinga.com/news/24/05/38642703/why-lyra-therapeutics-stock-is-down-93-today" target="_blank" rel="noreferrer noopener">reported&nbsp;in May 2024</a>.</li>
</ul>
Lyra also conducted a pooled data analysis of 64 CRS patients with small nasal polyps (grade 1) from the ENLIGHTEN 1 and ENLIGHTEN 2 trials. The data demonstrated a consistent positive trend compared to sham control over 24 weeks in multiple endpoints:
<ul class="wp-block-list">
<li>Improvement in 3CS with LYR-210 compared to sham control at week 24, starting as early as week 4.</li>
<li>Improvement in SNOT-22 score with LYR-210 compared to sham control at week 24, starting as early as week 4.</li>
<li>Improvements in percent ethmoid opacification with LYR-210 compared to sham control at week 20.</li>
<li>Improvements in nasal congestion score (NCS) with LYR-210 compared to sham control at week 24 for patients with moderate to severe NCS at baseline, starting as early as week 4.</li>
<li>Improved nasal polyp score with LYR-210 compared to sham control at week 24.</li>
</ul>
In March,&nbsp;the Food and Drug Administration (FDA) accepted for review&nbsp;GSK plc's&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSK#NYSE">GSK</a>) marketing application for&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/25/03/44084214/gsk-twice-yearly-depemokimab-reduces-nasal-polyp-size-improves-symptoms-in-chronic-rhinosinusitis-goes-under-fda-review-for-two-indications" rel="noreferrer noopener">depemokimab in two indications</a>:
<ul class="wp-block-list">
<li>Add-on maintenance treatment of asthma in adult and pediatric patients aged 12 years and older with type 2 inflammation characterized by an eosinophilic phenotype on medium- to high-dose inhaled corticosteroids (ICS) plus another asthma controller</li>
<li>Add-on maintenance treatment in adult patients with inadequately controlled chronic rhinosinusitis with nasal polyps (CRSwNP).</li>
</ul>
Price Action: LYRA stock is up 411.6% at $25.22&nbsp;during the premarket session at the last check on Monday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/biotech/25/05/45703024/pfizer-reports-survival-gains-in-colorectal-cancer-study-combo-therapy-cuts-death-risk-by-over-50" target="_blank" rel="noreferrer noopener">Pfizer Reports Survival Gains In Colorectal Cancer Study, Combo Therapy Cuts Death Risk By Over 50%</a></li>
</ul>
Photo: Shutterstock

Health Care

Movers

Trading Ideas

LYRA

Why Is Lyra Therapeutics Stock Surging Over 400% On Monday?

TRVI

Trevi Therapeutics shares are trading higher after the company announced positive topline results from its Phase 2b CORAL trial of Haduvio.

BlueLinx Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BXC#NYSE">BXC</a>), a leading U.S. wholesale distributor of building products, and Louisiana-Pacific Corporation ((LP Building Solutions, NYSE:<a href="https://www.benzinga.com/stock/LPX#NYSE">LPX</a>), a leading manufacturer of engineered wood building products, are pleased to announce the expansion of their distribution partnership to Springfield, Missouri. The expanded collaboration will include LP's renowned Siding Solutions brands and prefinished solutions, namely LP&#xAE; SmartSide&#xAE; Trim &amp; Siding and LP&#xAE; SmartSide&#xAE; ExpertFinish&#xAE; Trim &amp; Siding. This strategic move expands BlueLinx's stocking footprint of LP&#xAE; SmartSide&#xAE; to 19 locations, spanning five of BlueLinx's regions across the United States.
 &nbsp;

BlueLinx Holdings And LP Building Solutions Announce Expansion Of Distribution Partnership To Springfield, Missouri

Barclays analyst Andrew Mok downgrades Centene (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>) from Overweight to Equal-Weight and lowers the price target from $84 to $65.

Barclays Downgrades Centene to Equal-Weight, Lowers Price Target to $65

ATAI

atai Life Sciences shares are trading higher after the company announced it will merge with Beckley Psytech through a share combination agreement.

Press Releases

Invitation Homes Announces Tax Treatment of 2024 Dividends

Invitation Homes Promotes Tim Lobner to Chief Operating Officer

Invitation Homes Reports Fourth Quarter 2024 and Full Year 2024 Results

Invitation Homes to Participate in Citi's 30th Annual Global Property CEO Conference

Invitation Homes Announces Cash Dividend

Real Estate

Sibi Welcomes Marcus Ridgway to Board of Directors, Leading Innovation in Real Estate and Supply Chains

Invitation Homes Announces Dates for First Quarter 2025 Earnings Release and Conference Call

NextNav Announces Appointment of H. Wyman Howard and Lorin Selby to its Board of Directors

Comments

Invitation Homes

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL